»ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå º¸°í¼ : »ýü Àç·áº°, Èí¼öÀ²º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Bioabsorbable Stents Market Report by Biomaterial, Absorption Rate, Application, End User, and Region 2025-2033
»óǰÄÚµå
:
1701992
¸®¼Ä¡»ç
:
IMARC Group
¹ßÇàÀÏ
:
2025³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 145 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 4¾ï 3,800¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 7¾ï 8,650¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³âÀÇ ¼ºÀå·ü(CAGR)Àº 6.72%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.
»ýüÈí¼ö¼º ½ºÅÙÆ®(BRS)´Â Ç×Áõ½ÄÁ¦³ª À¯ÀüÀÚ·Î ÄÚÆÃµÇ¾î ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¿ëÇØµÇ¾î Ç÷°üÀÇ °³Å뼺À» ȸº¹Çϰí, ¹Ýµ¿À» À¯ÁöÇÏ¸é¼ ¸®¸ðµ¨¸µÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Àú°ü·ù·Î Ç÷·ù¸¦ À¯ÁöÇÏ¸é¼ ºÐÁöÁ¡ÀÇ Ç÷·ù¸¦ Á¶ÀýÇϰí, Ç÷°ü¸Á ¿µ¿ªÀ¸·Î °¡´Â Ç÷¾×·®À» Á¦ÇÑÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¶ÇÇÑ ½ÉÀå ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CT) ¹× ÀÚ±â°ø¸í¿µ»ó(MRI)À» ÅëÇÑ º´º¯ÀÇ ¿µ»óȵµ °³¼±ÇÕ´Ï´Ù. ¶ÇÇÑ ºñ°è°¡ ³²Áö ¾Ê¾Æ Ç÷°ü Àڱذú ¿°ÁõÀÌ Àû°í, °°Àº ºÎÀ§¿¡ ¹Ýº¹ Ä¡·á°¡ ¿ëÀÌÇÕ´Ï´Ù. ±× °á°ú, BRS´Â Àü ¼¼°è º´¿ø°ú ½ÉÀå¼¾ÅÍ¿¡¼ Æø³Ð°Ô Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.
»ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå µ¿Çâ :
°Ç°¿¡ ÇØ·Î¿î ½Ä½À°ü, ¿îµ¿ ºÎÁ·, ´ã¹è ¹× ¾ËÄÚ¿Ã °ú´Ù ¼·Ãë·Î ÀÎÇÑ ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀåÀ» ÁÖµµÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ¸·Èù µ¿¸ÆÀ» ¿¾î »ê¼Ò°¡ dzºÎÇÑ Ç÷¾×À» ü³»·Î ¿î¹ÝÇÏ´Â °æÇÇÀû °ü»óµ¿¸Æ ¼ºÇü¼ú(PCI)ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÇコÄÉ¾î »ê¾÷ÀÇ È®´ë¿Í ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, »ýüÈí¼ö¼º ½ºÅÙÆ®ÀÇ ÀåÁ¡¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾÷°è ÅõÀÚÀڵ鿡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¼ö¼ú ÈÄ ÅëÁõ °¨¼Ò, ¼ö¼ú ¹× ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò, ÀÔ¿ø ±â°£ ´ÜÃà, ȸº¹ ½Ã°£ ´ÜÃà µîÀ¸·Î ÀÎÇØ ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº °ü»óµ¿¸Æ ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ SLENDER Integrated Delivery System(IDS) °íÁ¤ ¿ÍÀÌ¾î ½Ã½ºÅÛ°ú DIRECT RX »ýüÈí¼ö¼º ±Þ¼Ó ±³Ã¼Çü ¾àÁ¦¿ëÃâ ½ºÅÙÆ®(DES) ½Ã½ºÅÛÀ» µµÀÔÇϱâ À§ÇØ ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ±¤¹üÀ§ÇÏ°Ô ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æú¸®¸Ó ±â¹Ý ½ºÅÙÆ® °³¹ß¿¡µµ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
- 2024³â ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå ±Ô¸ð´Â?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ 2025-2033³â ¼ºÀå·üÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
- COVID-19°¡ ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ »ýü Àç·áº° ½ÃÀå ÇöȲÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ Èí¼öÀ²º° ºñÁßÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ ¿ëµµº° ½ÃÀå ÇöȲÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ÇöȲÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
- ¼¼°è »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»çÀÇ ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
- Åé´Ù¿î ¾îÇÁ·ÎÄ¡
- Á¶»ç ¹æ¹ý
Á¦3Àå °³¿ä
Á¦4Àå ¼·Ð
Á¦5Àå ¼¼°èÀÇ »ýüÈí¼ö¼º ½ºÅÙÆ® ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : »ýü Àç·áº°
- Æú¸®¸Ó ±â¹Ý »ýüÈí¼ö¼º ½ºÅÙÆ®
- ±Ý¼Ó ±â¹Ý »ýüÈí¼ö¼º ½ºÅÙÆ®
Á¦7Àå ½ÃÀå ³»¿ª : Èí¼öÀ²º°
- ÀúÈí¼ö ½ºÅÙÆ®
- °í¼Ó Èí¼ö ½ºÅÙÆ®
Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°
- °ü»óµ¿¸Æ Áúȯ
- ¸»Ãʵ¿¸Æ Áúȯ
Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦11Àå SWOT ºÐ¼®
Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦13Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ¹ÙÀ̾îÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀïÀÇ Á¤µµ
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦14Àå °¡°Ý ºÐ¼®
Á¦15Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
- Abbott Laboratories
- Arterius Limited
- B. Braun SE
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Elixir Medical Corporation
- Kyoto Medical Planning Co. Ltd.
- Lepu Medical Technology(Beijing) Co. Ltd.
- Meril Life Sciences Pvt. Ltd.
- Reva Medical LLC
- Terumo Corporation
KSA
¿µ¹® ¸ñÂ÷
The global bioabsorbable stents market size reached USD 438.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 786.5 Million by 2033, exhibiting a growth rate (CAGR) of 6.72% during 2025-2033.
Bioabsorbable stents (BRS) are coated with an antiproliferative drug or gene that dissolves over time to restore vessel patency and permit remodeling while retaining recoil. It helps in regulating blood flow at branch points and limiting the amount of blood to areas of the vascular network while maintaining the flow at low perfusion. It also improves lesion imaging with cardiac computed tomography (CT) and magnetic resonance imaging (MRI). In addition, it leaves no residual scaffold, reduces vessel irritation and inflammation, and facilitates repeat treatments to the same site. As a result, BRS finds extensive applications in hospitals and cardiac centers across the globe.
Bioabsorbable Stents Market Trends:
The growing prevalence of cardiovascular diseases due to an unhealthy diet, physical inactivity, and excessive consumption of tobacco and alcohol represents one of the factors driving the market. Moreover, there is a rise in the utilization of percutaneous coronary intervention (PCI) procedures to open a blocked artery for carrying oxygen-rich blood through the body. This, along with the expanding healthcare industry, is contributing to the growth of the market. Besides this, the increasing awareness among the masses about the benefits of bioabsorbable stents is offering lucrative growth opportunities to industry investors. In addition, the growing demand for minimally invasive procedures due to less postoperative pain, fewer operative and postoperative complications, shortened hospital stay, and faster recovery times is positively influencing the market. Apart from this, key market players are extensively investing in research and development (R&D) activities to introduce SLENDER integrated delivery system (IDS) fixed-wire and DIRECT RX bioabsorbable rapid-exchange drug-eluting stent (DES) systems to treat coronary artery disease. They are also focusing on developing polymer-based stents, which is expected to bolster the growth of the market.
Key Market Segmentation:
Breakup by Biomaterial:
- Polymer-based Bioabsorbable Stents
- Metal-based Bioabsorbable Stents
Breakup by Absorption Rate:
- Slow-Absorption Stents
- Fast-Absorption Stents
Breakup by Application:
- Coronary Artery Disease
- Peripheral Artery Disease
Breakup by End User:
- Hospitals
- Cardiac Centers
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Reva Medical LLC and Terumo Corporation.
Key Questions Answered in This Report
- 1.What was the size of the global bioabsorbable stents market in 2024?
- 2.What is the expected growth rate of the global bioabsorbable stents market during 2025-2033?
- 3.What are the key factors driving the global bioabsorbable stents market?
- 4.What has been the impact of COVID-19 on the global bioabsorbable stents market?
- 5.What is the breakup of the global bioabsorbable stents market based on the biomaterial?
- 6.What is the breakup of the global bioabsorbable stents market based on the absorption rate?
- 7.What is the breakup of the global bioabsorbable stents market based on the application?
- 8.What is the breakup of the global bioabsorbable stents market based on the end user?
- 9.What are the key regions in the global bioabsorbable stents market?
- 10.Who are the key players/companies in the global bioabsorbable stents market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Bioabsorbable Stents Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Biomaterial
- 6.1 Polymer-based Bioabsorbable Stents
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Metal-based Bioabsorbable Stents
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Absorption Rate
- 7.1 Slow-Absorption Stents
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Fast-Absorption Stents
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Application
- 8.1 Coronary Artery Disease
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Peripheral Artery Disease
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Cardiac Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Arterius Limited
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 B. Braun SE
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Biotronik SE & Co. KG
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 SWOT Analysis
- 15.3.5 Boston Scientific Corporation
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Elixir Medical Corporation
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 Kyoto Medical Planning Co. Ltd.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Lepu Medical Technology (Beijing) Co. Ltd.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.9 Meril Life Sciences Pvt. Ltd.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.10 Reva Medical LLC
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.11 Terumo Corporation
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
°ü·ÃÀÚ·á